The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Soluble Urokinase Receptor and Acute Kidney Injury
Open accessAbstract
BACKGROUND: Acute kidney injury is common, with a major effect on morbidity and health care utilization. Soluble urokinase plasminogen activator receptor (suPAR) is a signaling glycoprotein thought to be involved in the pathogenesis of kidney disease. We investigated whether a high level of suPAR predisposed patients to acute kidney injury in multiple clinical contexts, and we used experimental models to identify mechanisms by which suPAR acts and to assess it as a therapeutic target. METHODS: We measured plasma levels of suPAR preprocedurally in patients who underwent coronary angiography and patients who underwent cardiac surgery and at the time of admission to the intensive care unit in critically ill patients. We assessed the risk of acute kidney injury at 7 days as the primary outcome and acute kidney injury or death at 90 days as a secondary outcome, according to quartile of suPAR level. In experimental studies, we used a monoclonal antibody to urokinase plasminogen activator receptor (uPAR) as a therapeutic strategy to attenuate acute kidney injury in transgenic mice receiving contrast material. We also assessed cellular bioenergetics and generation of reactive oxygen species in human kidney proximal tubular (HK-2) cells that were exposed to recombinant suPAR. RESULTS: The suPAR level was assessed in 3827 patients who were undergoing coronary angiography, 250 who were undergoing cardiac surgery, and 692 who were critically ill. Acute kidney injury developed in 318 patients (8%) who had undergone coronary angiography. The highest suPAR quartile (vs. the lowest) had an adjusted odds ratio of 2.66 (95% confidence interval [CI], 1.77 to 3.99) for acute kidney injury and 2.29 (95% CI, 1.71 to 3.06) for acute kidney injury or death at 90 days. Findings were similar in the surgical and critically ill cohorts. The suPAR-overexpressing mice that were given contrast material had greater functional and histologic evidence of acute kidney injury than wild-type mice. The suPAR-treated HK-2 cells showed heightened energetic demand and mitochondrial superoxide generation. Pretreatment with a uPAR monoclonal antibody attenuated kidney injury in suPAR-overexpressing mice and normalized bioenergetic changes in HK-2 cells. CONCLUSIONS: High suPAR levels were associated with acute kidney injury in various clinical and experimental contexts. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Acute kidney injury-epidemiology, outcomes and economics
Rewa, O., & Bagshaw, S. M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.282 · Cited by 734
Cited by
Acute kidney injury in the critically ill: an updated review on pathophysiology and management
Pickkers, P., Darmon, M., Hoste, E., Joannidis, M., Legrand, M., Ostermann, M., Prowle, J. R., Schneider, A., & Schetz, M. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06454-7 · Cited by 549
Reisinger, A. C., Niedrist, T., Posch, F., Hatzl, S., Hackl, G., Prattes, J., Schilcher, G., Meißl, A.-M., Raggam, R. B., Herrmann, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-96352-1 · Cited by 19
Jehn, U., Schütte-Nütgen, K., Henke, U., Pavenstädt, H., Suwelack, B., & Reuter, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83333-7 · Cited by 6
Metadata
- Authors
- Hayek, S. S., Leaf, D. E., Samman Tahhan, A., Raad, M., Sharma, S., Waikar, S. S., Sever, S., Camacho, A., Wang, X., Dande, R. R., Ibrahim, N. E., Baron, R. M., Altintas, M. M., Wei, C., Sheikh-Hamad, D., Pan, J. S.-C., Holliday, M. W., Januzzi, J. L., Weisbord, S. D., Quyyumi, A. A., & Reiser, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-30
- Volume
- 382
- Issue
- 5
- Pages
- 416-426
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3004063856
- Cited by
- 211
- References
- 2
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Soluble Urokinase Receptor and Acute Kidney Injury. https://app.cochat.ai/papers/10.1056/nejmoa1911481
- The paper
- Hayek, S. S., Leaf, D. E., Samman Tahhan, A., Raad, M., Sharma, S., Waikar, S. S., Sever, S., Camacho, A., Wang, X., Dande, R. R., Ibrahim, N. E., Baron, R. M., Altintas, M. M., Wei, C., Sheikh-Hamad, D., Pan, J. S.-C., Holliday, M. W., Januzzi, J. L., Weisbord, S. D., . . . Reiser, J. (2020). Soluble Urokinase Receptor and Acute Kidney Injury. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1911481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.